Cystinosis (nephropathic, juvenile, ocular)

What changes during this transition

Cystinosis is an autosomal recessive lysosomal storage disorder caused by mutations in the CTNS gene (17p13.2) encoding cystinosin, the lysosomal membrane transporter responsible for exporting cystine out of lysosomes. Loss of function produces progressive intracellular cystine accumulation in lysosomes throughout the body — the storage event that drives multi-organ damage. Three clinical forms shape the patient population editorially. Nephropathic infantile cystinosis (~95% of cases) is the most severe and the editorial center of gravity: presentation typically at 6-12 months of age with Fanconi syndrome (proximal renal tubular dysfunction producing glycosuria, generalized aminoaciduria, phosphaturia, bicarbonate wasting, polyuria, polydipsia, dehydration, electrolyte derangement, failure to thrive, and rickets from phosphate wasting), with progressive systemic manifestations through childhood including growth failure, hypothyroidism, hypogonadism, diabetes (often insulin-deficient from pancreatic beta-cell cystine accumulation), muscle wasting, swallowing problems, CNS involvement (cognitive issues and cerebral atrophy in a subset), and universal corneal crystal deposition. Without treatment, end-stage renal disease typically arrives by 10-12 years of age. Juvenile cystinosis presents in the late first decade or adolescence with milder progression. Ocular (non-nephropathic) cystinosis is adult-onset, with corneal crystals only and no systemic disease. Standard-of-care is cysteamine therapy, lifelong. Cysteamine is a small-molecule aminothiol that enters lysosomes and cleaves accumulated cystine into cysteine and a mixed cysteine-cysteamine disulfide, both of which can exit the lysosome via the PQLC2 transporter. The original FDA approval was cysteamine bitartrate (Cystagon, Mylan / Viatris) in 1994 with a demanding Q6h dosing schedule. The April 2013 FDA approval of delayed-release cysteamine bitartrate (Procysbi, Horizon Therapeutics, now Amgen) with Q12h dosing transformed adherence. Topical cysteamine eye drops (Cystadrops, Recordati Rare Diseases) received FDA approval in August 2020 for the universal corneal crystal manifestation. RENAL TRANSPLANTATION for ESRD progression is a critical inflection point and a load-bearing source of patient confusion: cystinosis does NOT recur in the transplanted kidney because the genetic defect is in the patient's lysosomes, not the kidneys, but renal transplantation does NOT cure systemic cystinosis — cysteamine must continue lifelong post-transplant to control cystine accumulation in eyes, muscle, thyroid, pancreas, brain, and other organs. The aging cystinosis cohort that emerged from the cysteamine + Procysbi era — transplant recipients living into adulthood with controlled but not cured disease — is the demographic for several community peptide questions. Investigational disease-modifying programs include the Avrobio AVR-RD-04 lentiviral HSC ex-vivo gene therapy program. Multi-jurisdictional patient infrastructure is mature: Cystinosis Research Foundation (cystinosisresearch.org), Cystinosis Foundation Ireland, European Cystinosis Network, Cystinose Network Deutschland. No peptide in the Juno library has a discovery-card-defensible cystinosis case. BPC-157 reaches the population through community 'tissue repair' framing that collides directly with intracellular cystine accumulation biology — the disease is a lysosomal storage event, not a tissue damage state. NMN reaches the population through general-aging framing in the aging cystinosis cohort. The GH-axis trio sits at a specific editorial complexity: GH-axis IS RELEVANT to cystinosis because somatropin is used for cystinosis-related growth retardation under pediatric endocrinology supervision in selected cases — but community GH-axis peptides are NOT interchangeable with somatropin under supervised endocrinology, and tesamorelin Rule 6 non-propagation is sharpest. Semaglutide is the coordination-of-care conversation for the aging adult cystinosis cohort with metabolic issues, with cysteamine GI side effects (nausea, vomiting, abdominal pain, altered gastric pH) overlapping load-bearingly with GLP-1 GI side effects during titration. Ninety-third deliberate non-elevation.